These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 1868442)

  • 1. Improved pharmacokinetics and tumor localization of immunotoxins constructed with the Mr 30,000 form of ricin A chain.
    Trown PW; Reardan DT; Carroll SF; Stoudemire JB; Kawahata RT
    Cancer Res; 1991 Aug; 51(16):4219-25. PubMed ID: 1868442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monensin in lipid emulsion for the potentiation of ricin A chain immunotoxins.
    Griffin T; Raso V
    Cancer Res; 1991 Aug; 51(16):4316-22. PubMed ID: 1868454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of growth of human tumor xenografts in athymic mice treated with ricin toxin A chain-monoclonal antibody 791T/36 conjugates.
    Byers VS; Pimm MV; Scannon PJ; Pawluczyk I; Baldwin RW
    Cancer Res; 1987 Oct; 47(19):5042-6. PubMed ID: 3497715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics in the rat of a panel of immunotoxins made with abrin A chain, ricin A chain, gelonin, and momordin.
    Wawrzynczak EJ; Cumber AJ; Henry RV; May J; Newell DR; Parnell GD; Worrell NR; Forrester JA
    Cancer Res; 1990 Dec; 50(23):7519-26. PubMed ID: 2253201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the pharmacokinetics and hepatotoxic effects of saporin and ricin A-chain immunotoxins on murine liver parenchymal cells.
    Blakey DC; Skilleter DN; Price RJ; Watson GJ; Hart LI; Newell DR; Thorpe PE
    Cancer Res; 1988 Dec; 48(24 Pt 1):7072-8. PubMed ID: 3263899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti-Thy 1.1 antibody.
    Blakey DC; Watson GJ; Knowles PP; Thorpe PE
    Cancer Res; 1987 Feb; 47(4):947-52. PubMed ID: 3492271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of an anti-CD7-ricin A chain immunoconjugate in a novel murine model of human T-cell leukemia.
    Fishwild DM; Aberle S; Bernhard SL; Kung AH
    Cancer Res; 1992 Jun; 52(11):3056-62. PubMed ID: 1375534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biodistribution of ricin toxin A chain-monoclonal antibody 791T/36 immunotoxin and influence of hepatic blocking agents.
    Byers VS; Pimm MV; Pawluczyk IZ; Lee HM; Scannon PJ; Baldwin RW
    Cancer Res; 1987 Oct; 47(20):5277-83. PubMed ID: 3498532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of intraperitoneal immunotoxins in a nude mouse model of human malignant mesothelioma.
    Griffin TW; Richardson C; Houston LL; LePage D; Bogden A; Raso V
    Cancer Res; 1987 Aug; 47(16):4266-70. PubMed ID: 3496960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient transplantation of human non-T-leukemia cells into nude mice and induction of complete regression of the transplanted distinct tumors by ricin A-chain conjugates of monoclonal antibodies SN5 and SN6.
    Hara H; Luo Y; Haruta Y; Seon BK
    Cancer Res; 1988 Aug; 48(16):4673-80. PubMed ID: 2969282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An immunotoxin composed of a monoclonal antitransferrin receptor antibody linked by a disulfide bond to the ribosome-inactivating protein gelonin: potent in vitro and in vivo effects against human tumors.
    Scott CF; Goldmacher VS; Lambert JM; Jackson JV; McIntyre GD
    J Natl Cancer Inst; 1987 Nov; 79(5):1163-72. PubMed ID: 3500356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of human tumor growth by intraperitoneal immunotoxins in nude mice.
    Marks A; Ettenson D; Bjorn MJ; Lei M; Baumal R
    Cancer Res; 1990 Jan; 50(2):288-92. PubMed ID: 2295069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain.
    Masui H; Kamrath H; Apell G; Houston LL; Mendelsohn J
    Cancer Res; 1989 Jul; 49(13):3482-8. PubMed ID: 2786451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo antitumor activity of ZENECA ZD0490, a recombinant ricin A-chain immunotoxin for the treatment of colorectal cancer.
    Calvete JA; Newell DR; Wright AF; Rose MS
    Cancer Res; 1994 Sep; 54(17):4684-90. PubMed ID: 8062265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of growth inhibition of a human ovarian adenocarcinoma cell line by free monoclonal antibodies and their corresponding antibody-recombinant ricin A chain immunotoxins.
    Ettenson D; Sheldon K; Marks A; Houston LL; Baumal R
    Anticancer Res; 1988; 8(4):833-8. PubMed ID: 3263079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocytosis of immunotoxin-791T/36-RTA by tumor cells in relation to its cytotoxic action.
    Byers VS; Pawluczyk IZ; Hooi DS; Price MR; Carroll S; Embleton MJ; Garnett MC; Berry N; Robins RA; Baldwin RW
    Cancer Res; 1991 Apr; 51(8):1990-5. PubMed ID: 2009518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antidisialoganglioside ricin A-chain immunotoxins show potent antitumor effects in vitro and in a disseminated human neuroblastoma severe combined immunodeficiency mouse model.
    Gottstein C; Schön G; Tawadros S; Kube D; Wargalla-Plate UC; Hansmann ML; Wacker HH; Berthold F; Diehl V; Engert A
    Cancer Res; 1994 Dec; 54(23):6186-93. PubMed ID: 7954465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of tumor-reactive immunotoxins in tumor-bearing mice: effect of antibody valency and deglycosylation of the ricin A chain on clearance and tumor localization.
    Fulton RJ; Tucker TF; Vitetta ES; Uhr JW
    Cancer Res; 1988 May; 48(9):2618-25. PubMed ID: 3258546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
    Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC
    Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
    Shah SA; Halloran PM; Ferris CA; Levine BA; Bourret LA; Goldmacher VS; Blättler WA
    Cancer Res; 1993 Mar; 53(6):1360-7. PubMed ID: 7680284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.